article thumbnail

Pivotal results from Trinity clinical trial for the chronic condition atopic dermatitis

Scienmag

The findings of a clinical trial by Trinity College Dublin researchers of treatment for atopic dermatitis have been published today in The Lancet journal (Friday, 21st May, 2021). Results of the clinical trial at […].

article thumbnail

Clariness, DailyBreath partner to drive recruitment in asthma trials

pharmaphorum

Patient recruitment specialist Clariness will deploy an app aimed at helping asthma patients monitor environment triggers and report symptoms in the clinical trials its support, thanks to a partnership with digital health firm DailyBreath.

Trials 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top Life Science News and Trends in 2023 at Xtalks

XTalks

The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy. Bayer’s Astepro (azelastine), an over-the-counter medication for cold, flu and allergies, led the pack in the first half of 2023 with 7.4 billion ad impressions.

article thumbnail

FDA approves Octapharma’s Octagam® 10% for adult dermatomyositis

Bioengineer

The FDA approval is based on the results of ProDERM (ClinicalTrials.gov Identifier: NCT02728752), a pivotal randomized clinical trial and the first study to evaluate the long term efficacy and safety of intravenous immunoglobulin (IVIg) for adults with dermatomyositis. residents.

article thumbnail

Fixed-dose combination of albuterol and budesonide (PT027) demonstrated significant benefits.

The Pharma Data

In March 2018, AstraZeneca and Avillion signed an agreement to advance PT027 through a global clinical development programme for the treatment of asthma. Asthma is a chronic, inflammatory, fluctuating respiratory disease 1 that affects as many as 339 million adults and children worldwide, 1 including over 25 million in the US.

Trials 52
article thumbnail

New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

The Pharma Data

These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14.

article thumbnail

Cancer-killing virus therapy shows promise against inoperable skin cancers

Scienmag

Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were not able to have their tumors surgically removed. The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and kill […].

Drugs 45